{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:18:15Z","timestamp":1793308695050,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NovoNordisk Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.metabol.2019.04.014","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T19:42:59Z","timestamp":1556221379000},"page":"46-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":235,"special_numbering":"C","title":["The incretin system in healthy humans: The role of GIP and GLP-1"],"prefix":"10.1016","volume":"96","author":[{"given":"Jens Juul","family":"Holst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.metabol.2019.04.014_bb0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.014_bb0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2337\/dc08-1195","article-title":"Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study","volume":"32","author":"Faerch","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2019.04.014_bb0015","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1089\/dia.2010.0239","article-title":"Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts","volume":"13","author":"Monnier","year":"2011","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.014_bb0020","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.014_bb0025","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2337\/dc16-0351","article-title":"Roles of the gut in glucose homeostasis","volume":"39","author":"Holst","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.metabol.2019.04.014_bb0030","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1017\/S0007114518000521","article-title":"A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients","volume":"119","author":"Samkani","year":"2018","journal-title":"Br J Nutr"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.014_bb0035","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41598-017-00453-9","article-title":"Relevance of the dietary glycemic index, glycemic load and genetic predisposition for the glucose homeostasis of Chinese adults without diabetes","volume":"7","author":"Cheng","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrendo.2014.202","article-title":"Gastric emptying and glycaemia in health and diabetes mellitus","volume":"11","author":"Phillips","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10.1016\/j.metabol.2019.04.014_bb0045","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1248\/bpb.33.1778","article-title":"Role played by afferent signals from olfactory, gustatory and gastrointestinal sensors in regulation of autonomic nerve activity","volume":"33","author":"Kitamura","year":"2010","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/EJE-13-0264","article-title":"Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty","volume":"169","author":"Plamboeck","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2019.04.014_bb0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-physiol-021115-105439","article-title":"Enteroendocrine cells: chemosensors in the intestinal epithelium","volume":"78","author":"Gribble","year":"2016","journal-title":"Annu Rev Physiol"},{"issue":"23","key":"10.1016\/j.metabol.2019.04.014_bb0060","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13507","article-title":"On the relationship between glucose absorption and glucose-stimulated secretion of GLP-1, neurotensin, and PYY from different intestinal segments in the rat","volume":"5","author":"Kuhre","year":"2017","journal-title":"Physiol Rep"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2019.04.014_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.014_bb0070","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s001250050735","article-title":"Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance","volume":"40","author":"Del","year":"1997","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.014_bb0075","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.2337\/dc10-0165","article-title":"Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the insulin resistance atherosclerosis study (IRAS)","volume":"33","author":"Lorenzo","year":"2010","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.014_bb0080","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol Rev"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.014_bb0085","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1007\/s00125-013-3003-0","article-title":"Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals","volume":"56","author":"Jacobsen","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2019.04.014_bb0090","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl. 2","key":"10.1016\/j.metabol.2019.04.014_bb0095","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.2337\/dc11-s227","article-title":"Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes","volume":"34","author":"Holst","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.014_bb0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/EJE-14-0314","article-title":"The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects","volume":"171","author":"Rhee","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2019.04.014_bb0105","article-title":"Comparative effects of proximal and distal small intestinal glucose exposure on glycemia, incretin hormone secretion, and the incretin effect in health and type 2 diabetes","volume":"14","author":"Zhang","year":"2019","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.014_bb0110","doi-asserted-by":"crossref","first-page":"E832","DOI":"10.1152\/ajpendo.00700.2009","article-title":"Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes","volume":"298","author":"Hare","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.014_bb0115","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/jc.2010-2435","article-title":"Impaired regulation of the incretin effect in patients with type 2 diabetes","volume":"96","author":"Bagger","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.04.014_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/cphy.c180013","article-title":"Physiology of the incretin hormones, GIP and GLP-1 - regulation of release and post-translational modifications","author":"Holst","year":"2019","journal-title":"Compr Physiol"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0125","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00125-017-4450-9","article-title":"Enteroendocrine K and L cells in healthy and type 2 diabetic individuals","volume":"61","author":"Jorsal","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.014_bb0130","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/diabetes.50.5.1030","article-title":"The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia","volume":"50","author":"Ahren","year":"2001","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.014_bb0135","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1210\/en.2014-1710","article-title":"An analysis of co-secretion and co-expression of gut hormones from male rat proximal and distal small intestine","volume":"156","author":"Svendsen","year":"2014","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.014_bb0140","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/33.10.3900195","article-title":"Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry","volume":"33","author":"Varndell","year":"1985","journal-title":"J Histochem Cytochem"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.014_bb0145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2362.1992.tb01464.x","article-title":"Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man","volume":"22","author":"Eissele","year":"1992","journal-title":"Eur J Clin Investig"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.014_bb0150","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.cmet.2008.11.002","article-title":"Glucose sensing in L cells: a primary cell study","volume":"8","author":"Reimann","year":"2008","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2337\/db14-0807","article-title":"Molecular mechnisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine","volume":"64","author":"Kuhre","year":"2014","journal-title":"Diabetes."},{"issue":"6","key":"10.1016\/j.metabol.2019.04.014_bb0160","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin- vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"issue":"18","key":"10.1016\/j.metabol.2019.04.014_bb0165","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1073\/pnas.89.18.8641","article-title":"Expression cloning of the pancreatic beta cell receptor for the gluco- incretin hormone glucagon-like peptide 1","volume":"89","author":"Thorens","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.014_bb0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/diabetes.53.1.5","article-title":"Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell","volume":"53","author":"Holz","year":"2004","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.014_bb0175","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1210\/edrv-16-3-390","article-title":"Cell and molecular biology of the incretin hormones glucagon- like peptide-I and glucose-dependent insulin releasing polypeptide","volume":"16","author":"Fehmann","year":"1995","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.014_bb0180","first-page":"1559","article-title":"Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling","volume":"15","author":"Trumper","year":"2001","journal-title":"Mol Endocrinol"},{"issue":"12","key":"10.1016\/j.metabol.2019.04.014_bb0185","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1600-0463.2003.apm1111207.x","article-title":"The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211","volume":"111","author":"Bock","year":"2003","journal-title":"APMIS"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.014_bb0190","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00125-004-1379-6","article-title":"Glucagon-like peptide-1 prevents beta cell glucolipotoxicity","volume":"47","author":"Buteau","year":"2004","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.014_bb0195","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0200","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.014_bb0205","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.014_bb0210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0026-0495(94)90164-3","article-title":"Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man","volume":"43","author":"Hvidberg","year":"1994","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0215","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2337\/db06-0738","article-title":"Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1","volume":"56","author":"de Heer","year":"2007","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0220","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.celrep.2014.09.030","article-title":"Glutamate acts as a key signal linking glucose metabolism to incretin\/cAMP action to amplify insulin secretion","volume":"9","author":"Gheni","year":"2014","journal-title":"Cell Rep"},{"issue":"2\u20133","key":"10.1016\/j.metabol.2019.04.014_bb0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0167-0115(03)00111-3","article-title":"Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects","volume":"114","author":"Vilsboll","year":"2003","journal-title":"Regul Pept"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.014_bb0230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.metabol.2019.04.014_bb0235","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients","volume":"45","author":"Vilsboll","year":"2002","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.014_bb0240","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2337\/db06-1033","article-title":"Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes","volume":"56","author":"Xu","year":"2007","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.014_bb0245","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bbrc.2007.08.115","article-title":"Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat","volume":"362","author":"Piteau","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"10.1016\/j.metabol.2019.04.014_bb0250","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","article-title":"Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine [in process citation]","volume":"140","author":"Hansen","year":"1999","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.014_bb0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides","volume":"85","author":"Mentlein","year":"1999","journal-title":"Regul Pept"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.014_bb0260","first-page":"952","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","volume":"80","author":"Deacon","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"2\u20133","key":"10.1016\/j.metabol.2019.04.014_bb0265","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0014-2999(96)00795-9","article-title":"Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor","volume":"318","author":"Knudsen","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.014_bb0270","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.regpep.2006.07.007","article-title":"The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects","volume":"137","author":"Vilsboll","year":"2006","journal-title":"Regul Pept"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.014_bb0275","first-page":"3575","article-title":"Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide","volume":"85","author":"Deacon","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"3 Pt 1","key":"10.1016\/j.metabol.2019.04.014_bb0280","first-page":"E458","article-title":"Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig","volume":"271","author":"Deacon","year":"1996","journal-title":"Am J Phys"},{"issue":"8","key":"10.1016\/j.metabol.2019.04.014_bb0285","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1007\/s00125-011-2168-7","article-title":"Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs","volume":"54","author":"Hjollund","year":"2011","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.014_bb0290","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/jc.2002-021053","article-title":"Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects","volume":"88","author":"Vilsboll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.014_bb0295","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Vilsboll","year":"2001","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.014_bb0300","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.014_bb0305","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.014_bb0310","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autneu.2003.11.001","article-title":"Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells","volume":"110","author":"Nakagawa","year":"2004","journal-title":"Auton Neurosci"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.014_bb0315","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2826.2010.01995.x","article-title":"Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats","volume":"22","author":"Baumgartner","year":"2010","journal-title":"J Neuroendocrinol"},{"issue":"Pt 19","key":"10.1016\/j.metabol.2019.04.014_bb0320","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1113\/jphysiol.2009.175067","article-title":"Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions","volume":"587","author":"Holmes","year":"2009","journal-title":"J Physiol"},{"key":"10.1016\/j.metabol.2019.04.014_bb0325","series-title":"Neuroendocrinology of appetite","first-page":"24","article-title":"Afferent endocrine control of eating","author":"Langhans","year":"2016"},{"issue":"5 Pt 1","key":"10.1016\/j.metabol.2019.04.014_bb0330","first-page":"G984","article-title":"Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow","volume":"275","author":"Wettergren","year":"1998","journal-title":"Am J Phys"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.014_bb0335","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diab.45.6.832","article-title":"Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I","volume":"45","author":"Orskov","year":"1996","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.014_bb0340","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.014_bb0345","first-page":"912","article-title":"Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations","volume":"76","author":"Nauck","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"30","key":"10.1016\/j.metabol.2019.04.014_bb0350","doi-asserted-by":"crossref","first-page":"21432","DOI":"10.1016\/S0021-9258(19)36628-1","article-title":"Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from Guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4","volume":"267","author":"Raufman","year":"1992","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.014_bb0355","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2337\/diabetes.48.1.86","article-title":"Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9\u201339","volume":"48","author":"Edwards","year":"1999","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.metabol.2019.04.014_bb0360","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1172\/JCI1349","article-title":"Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7- 36)amide in humans","volume":"101","author":"Schirra","year":"1998","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.metabol.2019.04.014_bb0365","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.2337\/db09-1253","article-title":"Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes","volume":"59","author":"Salehi","year":"2010","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0370","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gut.2004.059741","article-title":"Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans","volume":"55","author":"Schirra","year":"2006","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.014_bb0375","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.2337\/db13-0022","article-title":"Exaggerated glucagon-like peptide 1 response is important for improved beta-cell function and glucose tolerance after roux-en-Y gastric bypass in patients with type 2 diabetes","volume":"62","author":"Jorgensen","year":"2013","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.014_bb0380","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.2337\/db11-0203","article-title":"Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans","volume":"60","author":"Salehi","year":"2011","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.metabol.2019.04.014_bb0385","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.2337\/db16-0107","article-title":"Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9-39] as a GLP-1 receptor antagonist","volume":"65","author":"Nauck","year":"2016","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.014_bb0390","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.celrep.2018.10.018","article-title":"Insulin secretion depends on intra-islet glucagon signaling","volume":"25","author":"Svendsen","year":"2018","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.metabol.2019.04.014_bb0395","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/diabetes.47.7.1046","article-title":"Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor \u2212\/\u2212 mice","volume":"47","author":"Pederson","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2019.04.014_bb0400","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bcp.2017.02.012","article-title":"GIP(3\u221230)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release","volume":"131","author":"Sparre-Ulrich","year":"2017","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.014_bb0405","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bph.13384","article-title":"N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor","volume":"173","author":"Hansen","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.014_bb0410","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1053\/j.gastro.2010.01.049","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion","volume":"138","author":"Fujita","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.metabol.2019.04.014_bb0415","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2337\/db15-1541","article-title":"Evidence of extrapancreatic glucagon secretion in man","volume":"65","author":"Lund","year":"2016","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0420","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00125-017-4447-4","article-title":"GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study","volume":"61","author":"Gasbjerg","year":"2018","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.metabol.2019.04.014_bb0425","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The Gluco- and Liporegulatory and vasodilatory effects of glucose-dependent Insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2019.04.014_bb0430","article-title":"Separate and combined gluco-metabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in healthy individuals","volume":"9","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0435","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.regpep.2004.06.018","article-title":"The physiological role of GLP-1 in human: incretin, ileal brake or more?","volume":"128","author":"Schirra","year":"2005","journal-title":"Regul Pept"},{"key":"10.1016\/j.metabol.2019.04.014_bb0440","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.peptides.2017.11.021","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents","volume":"100","author":"Gasbjerg","year":"2018","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.metabol.2019.04.014_bb0445","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.metabol.2019.04.014_bb0450","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"Hojberg","year":"2009","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.metabol.2019.04.014_bb0455","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1210\/jc.2003-030738","article-title":"The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype","volume":"88","author":"Vilsboll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2019.04.014_bb0460","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1210\/jc.2010-0119","article-title":"Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects","volume":"95","author":"Hansen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2019.04.014_bb0465","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00125-012-2459-7","article-title":"Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes","volume":"55","author":"Jensen","year":"2012","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.metabol.2019.04.014_bb0470","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00125-005-1705-7","article-title":"Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors","volume":"48","author":"Holst","year":"2005","journal-title":"Diabetologia"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049519300861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049519300861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:21:24Z","timestamp":1758428484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049519300861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":94,"alternative-id":["S0026049519300861"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2019.04.014","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The incretin system in healthy humans: The role of GIP and GLP-1","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2019.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}